Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. …
In addition to identifying the tumor suppressor role of MAX in lung cancer, the group led by Montse Sanchez-Cespedes has unveiled a functional relationship between MAX and another tumor suppressor, BRG1, in virtue of which BRG1 regulates the expression of MAX through direct recruitment to the MAX promoter. However, the functional connection is even more complex. On one hand, the presence of BRG1 is required to activate neuroendocrine transcriptional programs and to up-regulate MYC-targets, such as glycolytic-related genes. Moreover, the depletion of BRG1 strongly hinders cell growth, specifically in MAX-deficient cells, heralding a synthetic lethal interaction. …
"The first step towards preventing lung cancer is avoiding cigarettes which cause 85 percent of diagnoses," said Dr. David Madtes, director of the Lung Cancer Early Detection and Prevention Clinic at SCCA. …
The authors’ findings come against the backdrop of rising cancer care costs in the United States, which were estimated at $124.6 billion in 2010 and could rise by 66 percent to $207 billion by 2020. "It is widely known that outcomes after cancer surgery vary widely, depending on interactions between patient, tumor, neoadjuvant therapy and provider factors," said Marah Short, a senior research analyst for the Baker Institute’s Health Policy Forum. "An area of cancer care that has received little attention is the influence of complications on medical outcomes and costs of care…
The therapy emerged from a sophisticated effort to reverse-engineer gene networks to identify genes that drive cancer. The same strategy could lead to many new therapies that disable cancer-causing genes no current drugs can stop, and it also can be used to find therapies for other diseases…
A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of research on nanomedicine-based approaches to treating cancer and offers insight into how researchers can best position nanomedicine-based cancer treatments for FDA approval. …
The system, presented at Gregorio Marañón Hospital, permits real-time interaction with the body of the patient (with its different tissues and cancer) as well as the radiotherapy applicator used to radiate the area affected by the tumor. This innovation will be used in the surgery of cancers treated with intraoperative radiotherapy in the hope of achieving greater precision in the radiation of potentially cancerous tissues after the removal of the tumor. The installation of this new equipment has entailed a complete remodeling of the operating room. …
Sophisticated computer modelling could be used to slowly move the table — known as a couch — and a radiation source in three dimensions to direct radiation precisely to the patient’s tumor, researchers have suggested. At the moment, a radiotherapy table can be angled during treatment, but there is no way to synchronise its rotation with a moving radiation beam. But with some modifications, an upgraded system could move both the patient and the beam while reducing the radiation dose of healthy tissue…
Seven hundred patients treated for colorectal cancer at three Cancer Treatment Centers of America hospitals completed service quality questionnaires measuring their levels of satisfaction with hospital operations and services, physicians and staff, and contained patient endorsements. Overall patient experience was measured by asking, “Considering everything, how satisfied are you with your overall experience with the institution?” Survey responses were correlated with median patient survival time from survey completion…
Presented at a poster session at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium by Carlos Barcenas, M.D., assistant professor in MD Anderson’s Breast Medical Oncology, the study is the first to look at the issue of over-use of staging procedures, including imaging and tumor markers in the diagnosis setting, specifically in younger, early-stage breast cancer patients. Over-testing and unnecessary procedures extends beyond cancer care across the healthcare continuum. …